PEG Linker Improves Antitumor Efficacy and Safety of Affibody-Based Drug Conjugates.
Ontology highlight
ABSTRACT: Antibody drug conjugates (ADCs) have become an important modality of clinical cancer treatment. However, traditional ADCs have some limitations, such as reduced permeability in solid tumors due to the high molecular weight of monoclonal antibodies, difficulty in preparation and heterogeneity of products due to the high drug/antibody ratio (4-8 small molecules per antibody). Miniaturized ADCs may be a potential solution, although their short circulation half-life may lead to new problems. In this study, we propose a novel design strategy for miniaturized ADCs in which drug molecules and small ligand proteins are site-specifically coupled via a bifunctional poly(ethylene glycol) (PEG) chain. The results showed that the inserted PEG chains significantly prolonged the circulation half-life but
SUBMITTER: Li Q
PROVIDER: S-EPMC7913616 | biostudies-literature | 2021 Feb
REPOSITORIES: biostudies-literature
ACCESS DATA